Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib.

导出 LinkOut

翻译打印收藏纠错

作者： Xiaoting,Chen ^[1] ; Wen,Zhao ^[2] ; Hejiang,Yu ^[3] ; Shuang,Wang ^[2] ; Chengjun,Wang ^[2] ; Yanan,Song ^[2] ; Xue,Meng ^[4] ; Jisheng,Li ^[2]

作者单位： Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China. ^[1] Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. ^[2] Department of Oncology, Yunyang County People's Hospital, Chongqing, China. ^[3] Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. ^[4]

关键词 FGFR3-IER5L fusion anlotinib driver gene mutation lung squamous cell carcinoma multi-target tyrosine kinase inhibitor

DOI 10.3389/fonc.2024.1391349

PMID 39421453

发布时间 2024-10-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2024年14卷

1391349页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除